Buy Mydocalm injection solution 10% 1ml No. 5 in pharmacies

The drug Mydocalm is intended for therapeutic purposes in neurology - it relieves pain syndromes, restores muscle tone, and normalizes trophism. It has a local anesthetic effect and membrane-stabilizing properties. By dilating blood vessels, it accelerates blood circulation and lymph outflow. Reduces tension in the musculoskeletal system.

Release form and composition

The product is available in 2 forms - tablets and injections. The main active ingredient is tolperisone hydrochloride, contained in volumes of 50 mg, 150 mg, 1 ml. The solution has a transparent color and a specific odor. Packaged in sterile ampoules with a capacity of 1 ml. One package contains 5 units.

Tablets are round, biconvex, white, with digital engraving on one side. The smell is characteristic, but weak. There are 2 types available - 50 and 150 mg of active ingredient, each package contains 30 pieces.

Composition of tablets (internal filling):

The shell contains the following (at 50 mg and 150 mg respectively):

• colloidal silicon dioxide - 0.045/0.089 mg;
• titanium dioxide - 0.244/0.487 mg;
• lactose monohydrate - 0.392/0.785 mg;
• hypromellose - 3.927/7.854 mg.

The 150 mg tablets additionally contain macrogol 6000 in the amount of 0.785 mg.

Auxiliary composition of the injection solution:

• lidocaine hydrochloride - 2.5 mg;
• E218 (methyl parahydroxybenzoate);
• Diethylene glycol monoethyl ether.

pharmachologic effect

Mydocalm belongs to the pharmacotherapeutic group of centrally acting muscle relaxants. ATX encoding - M03BX04.

Pharmacodynamics

The mechanism of action is not fully understood. The therapeutic benefit of the active substance is achieved through an inhibitory effect on the spinal reflex pathways and an inhibitory effect on the descending pathways. The drug inhibits voltage-gated calcium channels and inhibits the activity of sodium channels, thereby eliminating the negative effect. During the secondary action, the path for calcium ions to enter the synapses is blocked, which leads to blocking the process of transmitter removal.

Pharmacodynamic properties:

• membrane stabilizing effect;
• decreased electrical excitability in afferent fibers and motor neurons;
• acceleration of peripheral blood circulation;
• pain relief;
• antiadrenergic effect;
• high degree of affinity for nerve tissues, due to which the substance is concentrated in the brain stem and spinal cord.

Pharmacokinetics

Pharmacokinetic properties of the tablet form

After oral administration, the substances are quickly absorbed and distributed throughout the body from the gastrointestinal tract, concentrating in maximum quantities after 30-60 minutes. Pronounced first pass metabolism ensures bioavailability of up to 20%. To increase the percentage of bioavailability, it is necessary to take fatty foods, but at the same time the time of maximum concentration increases by 20-30 minutes. The substance is metabolized in the renal system and liver, so 99% is excreted through the urinary fluid. The half-life is 2 and a half hours.

Pharmacokinetics of injection solution

Liquid tolperisone, as in tablets, is metabolized in the liver and kidneys. Half-life occurs after an hour and a half. Lidocaine is completely adsorbed. If the drug is administered intravenously, the maximum concentration of the active substance in the blood plasma is observed after 30-40 minutes, the relationship with proteins is 60-80%.

The injection solution instantly spreads throughout the tissues, penetrates the placental (40%) and blood-brain protective barriers. Cleavage occurs due to dealkylating amino groups and microsomal enzymes that break the amide bond, forming active metabolites. 10% of the solution is excreted in urine, the rest in bile, but some is reabsorbed in the intestine.

Based on preclinical studies on toxicity and safety, it was found that the drug does not pose a threat to the reproductive system of the human body.

Pharmacodynamics and pharmacokinetics

Tolperisone, which is part of the solution, has not been fully studied. It is known that the substance is characterized by high affinity (from the Latin affinitas - “kinship”) for nervous tissue . Its highest concentrations are found in the brain stem , spinal cord and PNS (peripheral nervous system).

The most significant is the ability of Tolperisone to have an inhibitory effect on reflex centers in the spinal cord . It is likely that such an effect, combined with an inhibitory effect on the efferent (descending) pathways, determines the therapeutic effect of Tolperisone .

Tolperisone has the ability to prevent the destruction of cell membranes, and also reduces the electrical excitability of motor neurons and primary afferent processes of nerve cells that conduct sensitive impulses from various tissues and organs to the CNS (central nervous system).

In addition, the substance:

• reduces the threshold of pain sensitivity;
• blocks spinal trunk monosynaptic and polysynaptic reflexes;
• selectively reduces the activity of the caudal part of the complex of nerve structures localized in the central parts of the tegmentum of the brain along its entire length (the so-called reticular formation of the brain stem );
• reduces muscle ;
• reduces pathologically increased muscle hypertonicity ;
• reduces muscle rigidity;
• reduces the intensity of pain;
• facilitates voluntary active movements and increases their amplitude;
• increases the intensity of peripheral blood flow;
• has a vasodilating effect;
• prevents the release of mediators at synapses (a similar effect develops, most likely, secondarily, due to the inhibition of the flow of calcium ions (Ca2+) into presynaptic (nerve) endings).

Tolperisone has a weak antispasmodic effect and has the properties of a centrally acting H-anticholinergic.

This is expressed in the ability of the substance to prevent or weaken the predominantly nicotine-like effect of acetylcholine (the main neurotransmitter in the parasympathetic nervous system ) and cholinomimetic drugs.

, Tolperisone a pronounced effect on .

Tolperisone is well tolerated (in particular, it is well tolerated by elderly patients), does not provoke the development of cardiotoxic effects and cognitive , and has no sedative effect .

The safety profile of Tolperisone is based on data from clinical studies that included patients with muscle hypertonicity of various etiologies, as well as on spontaneous reports of any adverse reactions.

During preclinical studies of pharmacological safety, the level of toxicity during a course of use, genotoxicity (the ability to potentially provoke gene mutations or the development of tumors), and the ability to affect the reproductive function, no specific risks for patients were identified.

Undesirable effects were noted only in cases where the administered dose significantly exceeded the maximum permissible for humans. The latter indicates little significance for clinical use.

Lidocaine acts as a local anesthetic and is characterized by the ability to dose-dependently inhibit the activity of Na+ channels (voltage-dependent sodium channels), which, in turn, prevents the generation of impulses at the endings of sensory nerve fibers and the conduction of impulses along them. Moreover, the substance suppresses not only pain impulses, but also impulses of other modalities.

When applied topically, it provokes vasodilation without causing a local irritant effect.

When dosing the drug Mydocalm-Richter in accordance with the schemes given in the instructions for use, lidocaine does not have a systemic effect on the patient’s body.

Tolperisone hydrochloride is intensively biotransformed in the tissues of the liver and kidneys , after which it is almost completely excreted from the body by the kidneys metabolic products (more than 99% of the substance entering the body). exact data regarding the pharmacological activity of the metabolites .

After administration of Mydocalm solution intravenously, the half-life of Tolperisone hydrochloride is one and a half hours.

Lidocaine hydrochloride , entering the body, is completely absorbed. Moreover, the rate of absorption depends on the site of administration of the drug and its dose. The time during which the maximum concentration of the substance is reached after intramuscular injection varies from half an hour to 45 minutes.

to plasma proteins by 50-80%. The distribution of the substance in various tissues and organs occurs quite quickly.

It has the ability to penetrate the blood-brain barrier (BBB) ​​and plasma barriers and is excreted in the breast milk of a nursing woman. Moreover, the concentration of lidocaine in milk is 40% of the concentration of the substance in blood plasma .

Lidocaine metabolized in liver (approximately 90-95%) under the influence of microsomal liver enzymes through dealkylation of the amino group and cleavage of the amide bond. As a result of this process, pharmacologically active metabolites are released.

From the patient's body, lidocaine is excreted along with bile (in this case, the substance is partially reabsorbed in the gastrointestinal tract ) and kidneys (up to 10% of lidocaine is excreted unchanged).

Indications for use of Mydocalm

Tablets and injections are prescribed for the following pathological conditions:

• hypertonicity of the skeletal muscles with damage to the central nervous system of an organic nature - stroke and diseases of the pyramidal tracts of the brain, multiple sclerosis, encephalomyelitis, etc.;
• cerebral palsy;
• contracture that occurs against the background of osteochondrosis, osteoarthrosis, spondylosis;
• stiffness of movement, impaired speech due to spasticity of skeletal muscle tissue;
• muscular dystonia;
• spinal dystrophy;
• inflammatory processes in the spinal cord and brain against the background of intoxication of the body, allergies and viral damage;
• after spinal cord injury and surgery;
• cervical and lumbar syndrome;
• arthrosis of large joints.

Mydocalm is prescribed in complex therapy as an adjuvant for the following pathologies:

• obliterating diseases of the circulatory system - thromboangiitis, diabetic angiopathy, arteriosclerosis, Raynaud's syndrome, diffuse scleroderma;
• pain during menstruation;
• cholelithiasis;
• haemorrhoids;
• colic in the kidneys;
• threat of miscarriage with high uterine tone;
• impaired vascular innervation - intermittent angioedema dysbasia, acrocyanosis;
• diffuse scleroderma with fibroids;
• complications of diabetes.

Side effects of Mydocalm

Adverse reactions occur when the drug is taken incorrectly (often uncontrolled self-medication) and against the background of contraindications.

Negative effect of the tablets:

• a sharp decrease in blood pressure;
• nausea and vomiting;
• abdominal discomfort;
• headache;
• muscle weakness.

Side effects from injections:

• difficulty breathing;
• minor loss of coordination of movements caused by muscle weakness;
• heart failure.

In both cases, an allergic reaction is possible:

• skin rashes;
• itching;
• swelling;
• hives;
• shortness of breath and bronchospasm;
• Quincke's edema (affects the face and genitals);
• anaphylactic shock.

Overdose

Data on cases of overdose with Mydocalm are limited. The drug is characterized by a wide therapeutic index.

According to preclinical studies of the acute toxicity of the solution, when the drug is administered in doses significantly higher than therapeutic, symptoms such as:

• disorders of the coordination of movements of various muscles in the absence of muscle weakness in the patient (ataxia );
• tonic-clonic seizures;
• difficulty breathing (up to its complete stop).

specific antidote for Tolperisone . If the recommended dose is exceeded, it is recommended that the patient undergo gastric lavage. The following are symptomatic and supportive therapies.

Methods of use and dosage Mydocalm

Tablet Mydocalm is taken orally. The dosage depends on the severity of the lesion, the individual characteristics of the body and the type of disease. The daily norm is divided into 3 equal doses. On average it is from 150 to 450 mg. At the initial stages, a minimum dose is prescribed. The tablets are taken after meals with water.

Dosage depending on age category:

• from 3 to 6 years: per 1 kg of weight 5 mg;
• from 6 to 14 years: per 1 kg of body weight from 2 to 4 mg;
• adolescents over 14 years of age and adults: at least 50 mg twice daily.

The injection solution is administered in different ways:

1. Intravenously. Use 1 ml once a day.
2. Intramuscularly. It is prescribed in a daily dosage of 200 mg (2 ml), divided into 2 times.

Interaction

It is known that tolperisone has an effect on the central nervous system, but despite this there is no sedative reaction. Therefore, there are no restrictions on the use of Mydocalm:

• a muscle relaxant goes well with sedatives;
• used with sleeping pills;
• enhances the effect of antihypertensive medications based on clonidine;
• used with anesthetic agents;
• prescribed along with psychotropic groups;
• interacts with muscle relaxants.

Most often, Mydocalm is combined in one treatment regimen with Milgamma and Movalis for pathological disorders of the musculoskeletal system. This allows you to significantly reduce the pain threshold, relieve spasms, and restore muscle tone. In addition, it has a neuroprotective effect, which eliminates inflammatory processes and stops the degenerative development of diseases.

Prescribing Mydocalm injections for pregnant and lactating women

Animal studies have shown that Tolperisone does not have a negative effect on the intrauterine development of the fetus. However, to date there is no data on the safety of the drug for the treatment of pregnant and lactating women .

The drug in the form of an injection solution is contraindicated in the first trimester . It is allowed to be prescribed at a later date, but only when, in the opinion of the doctor, the expected therapeutic effect for the woman exceeds the risk of complications for the fetus or infant.

Since it is not known for sure whether Tolperisone pass into breast milk, the use of the drug during breastfeeding is contraindicated. If it is still not possible to avoid Mydocalm-Richter injections, the issue of stopping lactation should be decided during the course of treatment.

Mydocalm during pregnancy and lactation

Mydocalm in tablets and injections is prohibited for use by children under 3 years of age. Accordingly, it is not recommended to take the drug during pregnancy. The medicine does not have a teratogenic effect, however, studies have not been conducted on women during pregnancy and breastfeeding. Based on this, tablets or injections can be prescribed, but in minimal daily dosages - mainly in cases where it is vital for the mother. You will have to stop breastfeeding your baby.

Contraindications

Contraindications to the use of Mydocalm-Richter are:

• hypersensitivity to any of the active or auxiliary substances included in the drug (including lidocaine and other amide drugs that have a local anesthetic effect);
• myasthenia gravis in severe form;
• pregnancy;
• lactation.

The drug also has age restrictions: injections of the drug are contraindicated for persons under 18 years of age.

Analogues of Mydocalm

Analogues are drugs that have the same pharmacological effect. The products may contain a similar or different active substance and act on the body through the same or a different mechanism. Mydocalm has a sufficient number of analogues. Therefore, it is worth understanding in more detail which of the presented remedies is better or worse than Mydocalm.

Which is better: Sirdalud or Mydocalm?

What do the drugs have in common:

1. Both are muscle relaxants, but have different compositions.
2. The mechanism of action is the same - nerve impulses are blocked.
3. General indications are problems with the musculoskeletal system.
4. There is no big difference in cost.

What is the difference:

1. Sirdalud is based on tisinidine, which acts on presynoptic alpha-2 receptors in the spinal cord. This leads to the transmission of excitation polysynaptically and blocking of interneurons. Mydocalm consists of tolperisone, which inhibits increased excitability by regulating the functionality of the reticular formation in the caudal zone, and also affects peripheral nerve endings.
2. The first drug is concentrated in maximum quantities after 60 minutes, the second - 30.
3. Sirdalud is produced only in the form of tablets, Mydocalm is also available in an injection solution.
4. Sirdalud provokes dangerous disorders in the liver, which is why the patient must monitor the functionality of the liver tissue (conduct an examination).
5. Mydocalm has fewer adverse reactions. For example, the concentration of attention does not decrease, the pulse does not slow down, the mucous membranes do not dry out, powerlessness is not felt, and the activity of the gastrointestinal tract is not disrupted.

Which is better: Tolisor or Mydocalm?

Both drugs are based on tolperisone, so the mechanism of action is similar. But there are differences between them:

1. Mydocalm loses its therapeutic effect much faster. The result is noticeable after three days of use.
2. Tolisor has more side effects because it has not passed all clinical trials.
3. Although the two remedies act identically, there are still differences. Mydocalm has a central effect, while Tolisor affects individual parts of the brain. At the same time, the anesthetic effect is slightly lower and there is no effect on the overall functioning of the central nervous system.
4. Mydocalm, if necessary, is allowed for use during pregnancy; Tolisor is strictly prohibited.

Thus, Mydocalm is an original drug that has passed all stages of clinical trials and is considered safe.

Which is better: Movalis or Mydocalm?

The main active ingredient in Movalis is meloxicam. The drug belongs to the anti-inflammatory group, and not to muscle relaxants. Based on this, comparing the two means is meaningless. However, both Movalis and Mydocalm cope well with pain syndromes in the musculoskeletal system. Only the first, in addition to pain relief, relieves inflammation, and the second relieves pain and restores muscle tone.

Being a non-steroidal drug, Movalis suppresses the activity of COX-1 and 2, and Mydocalm suppresses the excitability of nerve cells. Quite often, drugs are prescribed in one therapeutic regimen, as they combine well with each other, enhancing each other’s effects. In this case, the doctor must select an individual dosage depending on the indications.

Which is better: Tolperisone or Mydocalm?

Mydocalm and Tolperisone are completely identical, since they contain the same active substance. Medicines are produced in the same proportions - 50 mg, 150 mg (in tablet form). Tolperisone - in the form of dragees, Mydocalm - tablets, injection solution. In terms of speed of action, the second is considered faster; general weakness is not noted as a side reaction. Tolperisone should not be taken until the age of 18, and Mydocalm is prescribed from the age of 3. The cost of the latter is lower (on average 100-150 rubles). It is impossible to determine which of them is better, since the level of therapeutic effect largely depends on the specific characteristics of the body.

Which is better: Meloxicam or Mydocalm?

Meloxicam belongs to the group of non-steroidal anti-inflammatory drugs that are aimed at relieving pain and inflammation in the musculoskeletal system. Mydocalm is a muscle relaxant that eliminates pain and restores muscle tone. Consequently, the drugs have different purposes, but are actively used together. However, Meloxicam is prescribed for the same pathologies as Mydocalm (osteochondrosis, arthrosis). Despite the fact that the drugs are different, they are similar for relieving pain. What exactly to take should be decided by the attending physician, based on the cause of the pain.

Which is better: Mexidol or Mydocalm?

Mexidol's active substance is ethylmethylhydroxypyridine succinate, and Mydocalm's is tolperisone. But the drugs have similarities in the composition of the auxiliary components - talc, titanium dioxide, lactose monohydrate (tablet form). Medicines are aimed at eliminating neurological problems:

• reducing the level of muscle spasms;
• pain relief.

This allows the use of drugs to treat the same diseases: spondylosis, arthrosis, contracture, muscle hypertonicity, injuries, osteochondrosis, etc. The mechanism of influence on the body is almost equivalent, so the drugs are interchangeable. However, Mexidol additionally has a nootropic anxiolytic effect. Moreover, it is advisable to use them together as complementary agents.

Which is better: Baclofen or Mydocalm?

Medicines belong to one group - centrally acting muscle relaxants. Mydocalm contains tolperisone, Baclofen contains baclofen. General indications:

• high muscle tone;
• spinal injuries;
• impaired cerebral circulation;
• cerebral palsy;
• diseases affecting the muscular system of the back;
• spinal cord pathologies;
• motor neuron dysfunction.

Baclofen is additionally used for cerebral palsy, withdrawal and affective states against the background of alcoholism and drug addiction. The drugs have some side effects, but Baclofen has more contraindications: the age at which it can be taken is 12 years, atherosclerosis, cerebrovascular insufficiency. Baclofen should be taken with extreme caution, as the slightest overdose can cause cardiac and respiratory arrest.

Which is better: Tizanidine or Mydocalm?

Tizanidine is based on the active substance of the same name and is part of the group of centrally acting muscle relaxants. The mechanism is to stimulate presynaptic alpha-2 adrenergic receptors, due to which transmitter amino acids are suppressed, which restores the tonic state of skeletal muscles. This indicates that Tizanidine acts on the body in the same way as Mydocalm, but taking the drug is allowed only from the age of 18 (Mydocalm - from 3 years). The choice is influenced by the type of disease, the individual characteristics of the patient’s body, the severity of the disease and the age category.

Mydocalm for osteochondrosis

With osteochondrosis of any part of the spine, muscle tension is noted and spastic pain appears. To eliminate such signs, it is customary to prescribe centrally acting muscle relaxants (the central parts of the nervous system regulate muscle tone). Therefore, Mydocalm is prescribed quite often.

Advantages of using Mydocalm for osteochondrosis syndrome:

1. The muscle relaxant effect of the drug is selective. Namely: excitability in muscle fibers decreases, but nerve impulses are not suppressed. This makes it possible to maintain muscle strength during movements, so that posture remains unchanged.
2. Mydocalm can be used for a long period, since the tolerability of the active substance is high (no addiction, no new adverse reactions appear).
3. There are no effects of mental and physical inhibition. The person continues to engage in usual activities, does not lose ability to work, and does not become sleepy.
4. Tolperisone interacts with many drugs that are intended to treat osteochondrosis.
5. Anesthetic properties make it possible to reduce the dosage of nonsteroids.

special instructions

Mydocalm can be combined with various sedatives; however, the potentiating effect of Mydocalm on general anesthesia and peripheral muscle relaxants should be taken into account. There are no data on unwanted toxic drug interactions with Mydocalm.

[!] Taking Mydocalm does not cause sedation and is not a limitation for driving, operating complex mechanisms and other actions that require increased attention and speed of psychomotor reactions.

Mydocalm for headaches

A headache causes a lot of unpleasant sensations, so every person tries to stop it as quickly as possible. To do this, people take analgesics, non-steroidal anti-inflammatory drugs, and other things that are intended for pain relief. Undoubtedly, there is a certain effect: the pain syndrome is reduced for a while. But the cause of the pain is not eliminated. Mydocalm, being a powerful muscle relaxant, shows excellent results in the fight against headaches, as it has relaxing properties.

Unfortunately, it is not always possible to achieve the desired effect with the help of a muscle relaxant. This phenomenon is associated with the cause of pain in the brain. It turns out that the main indication is tension and spasm. This can be spasm of the muscular system, squeezing of blood vessels, pinching of nerves, which is why tension appears.

The fact is that muscle strain contributes to vasoconstriction and slows down the blood supply process (ischemia), which negatively affects nutritional functions. Thus, beneficial substances do not reach the muscles, and stagnation occurs. Mydocalm dilates blood vessels, which accelerates blood circulation and nourishes muscle fibers. At the same time, the anesthetic effect relieves spasms.

Problems for which it is advisable to take Mydocalm (in the presence of headaches):

• osteochondrosis of the cervical spine;
• migraine;
• spinal automaticity;
• multiple sclerosis;
• neurological diseases;
• cerebral palsy;
• encephalopathy.

Mydocalm for intercostal neuralgia

In some diseases of the spinal column, the intercostal nerves are compressed, causing intercostal neuralgia syndrome to occur. In this case, the patient experiences severe pain that limits movement. To suppress it, various drugs are prescribed - non-steroidal anti-inflammatory drugs, antispasmodics. But all of them only relieve pain and reduce the inflammatory process, so muscle relaxants, in particular Mydocalm, become the best treatment option.

With intercostal neuralgia due to pinched nerve endings, the muscular system of the back begins to reflexively contract, which significantly increases its tone. Against this background, a spasm of blood vessels develops, which leads to the accumulation of lactic acid in the tissues. This waste product has a toxic effect, which increases pain. This is how pain occurs between the ribs.

Mydocalm is aimed at eliminating vasospasm, reducing muscle tone, thereby breaking the “vicious circle” of ongoing processes. Therefore, the drug not only relieves discomfort, but also has a therapeutic effect, that is, it eliminates the cause of the pain syndrome.

In case of a neuralgic condition, Mydocalm is best used as an injection, but this depends on the strength of the pain threshold and the degree of neglect of the pathology. How to use the product correctly:

• in the first days (from 5 to 10) Mydocalm is administered intramuscularly twice a day;
• then the same drug is prescribed in tablet form.

The duration of therapy is determined by the attending physician.

Reviews about Mydocalm-Richter

The drug is successfully used to treat patients in many countries around the world. It is well tolerated and does not have a sedative effect, which is confirmed by numerous randomized studies in which placebo was used.

Reviews of Mydocalm-Richter injections left by patients are overwhelmingly positive. The drug is described as an effective and affordable medicine. Only rarely can you find negative reviews that state the ineffectiveness of treatment with Mydocalm injections.

Some people note that the greatest effectiveness in the treatment of certain diseases (in particular, osteochondrosis ) was achieved using Mydocalm in combination with other medications.

Doctors confirm this opinion and often prescribe Mydocalm injections in combination with vitamin preparations with a general strengthening effect (for example, Milgamma or Kombilipen ) and non-steroidal anti-inflammatory drugs (for example, Movalis ).